SCHEMBL5131129

SCHEMBL5131129

CCc1cccc(CN(C[C@@H](O)[C@@H](N)Cc2cc(F)cc(F)c2)C(=O)CCCC(=O)Nc2ccc(F)cc2F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.41
RAB9A P51151 2/20 0.41
CTSD P07339 2/20 0.37
BACE1 P56817 2/20 0.37
ALDH1A1 P00352 1/20 0.37
CTDSP1 Q9GZU7 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
SOAT1 P35610 1/20 0.37
NPC1 O15118 1/20 0.36
HDAC3 O15379 2/20 0.36
HDAC1 Q13547 1/20 0.35
PKM P14618 1/20 0.35
HSD17B10 Q99714 1/20 0.34
BRD4 O60885 1/20 0.34
TSHR P16473 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
GAA P10253 1/20 0.34
TP53 P04637 1/20 0.34
CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5126397 0.88 POLB (0.35) POLBRAB9ACTSDBACE1ALDH1A1
SCHEMBL5116565 0.86 BACE1 (0.38) POLBCTSDBACE1ALDH1A1HDAC3
SCHEMBL5125902 0.85 KMT2A (0.41) RAB9ACTSDBACE1ALDH1A1NPC1
SCHEMBL5579835 0.85 PPARA (0.38) CTSDBACE1ALDH1A1HDAC3HDAC1
SCHEMBL5131035 0.84 LMNA (0.41) POLBCTSDBACE1HDAC3HDAC1
SCHEMBL5120535 0.82 EPHX2 (0.41) POLBCTSDBACE1ALDH1A1NPC1
SCHEMBL5127424 0.82 KMT2A (0.44) POLBCTSDBACE1ALDH1A1HDAC3
SCHEMBL5130327 0.81 BACE1 (0.40) POLBCTSDBACE1CTDSP1HDAC3
SCHEMBL5125565 0.80 BACE1 (0.39) CTSDBACE1
SCHEMBL5126595 0.80 LMNA (0.41) RAB9ACTSDBACE1NPC1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome ELAN PHARMACEUTICALS, INC. 2008-07-03 US disclosed
US-7294642-B2 1,3-Diamino-2-hydroxypropane pro-drug derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome BACE1, APP, BACE2 POLB 656/4885RAB9A 539/4885CTSD 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.